Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or...

cryptococcus neoformans is the most incriminated fungal pathogen causing meningitis in acquired immune deficiency syndrome (aids) patients, and is known to constitute a major cause of deaths in aids patients. this study aimed to determine the sero-prevalence and effect of cd4 count on seropositivity for cryptococcus neoformans antigen (crag) in antiretroviral- naïve (art-naïve) aids patients. t...

pneumonia and mucosal candidiasis in previously healthy individuals in the USA in 1981, the pandemic of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) has reached alarming proportions. The current WHO/ UNAIDS(2004)reporthasestimated38million people living with this infection worldwide; 60–90 000 in the UK. Almost 50% of these are females and the numbe...

Human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), first appeared in NSW in the early 1980s. Since then, HIV has had a significant affect on public health, causing over 3,400 deaths from AIDS and 12,500 infections. Within Australia, most cases of HIV infection have been reported in NSW. This article describes the effect that the HIV epidemic has...

The effect of antiretroviral therapy (ART) in preventing human immunodeficiency virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the San Francisco gay community over the next 10 years was predicted. A transmission model was coupled with a statistical approach that enabled inclusion of a high degree of uncertainty in the potential treatment effects of ART (...

High-titer anti-human immunodeficiency virus (HIV) antibodies reduced circulating HIV viral burden and has shown promise in previous small uncontrolled studies, warranting a larger controlled study of passive hyperimmune therapy (PHT) in persons with acquired immunodeficiency syndrome (AIDS). The objective of this study was to determine the efficacy and safety of PHT in 220 AIDS subjects in a 1...

Uganda provides the clearest example that human immunodeficiency virus (HIV) is preventable if populations are mobilized to avoid risk. Despite limited resources, Uganda has shown a 70% decline in HIV prevalence since the early 1990s, linked to a 60% reduction in casual sex. The response in Uganda appears to be distinctively associated with communication about acquired immunodeficiency syndrome...

In the natural history of Human Immunodeficiency Virus Type-1 (HIV-1) infection, many studies included the participants who were seropositive at time of enrollment. Estimation of the unknown times since exposure to HIV-1 in the prevalent cohorts is of primary importance for estimation of the incubation period of Acquired Immunodeficiency Syndrome (AIDS). To estimate incubation period of AIDS we...

Increased apoptosis of CD4' T cells is considered to be involved in CD4' T-cell depletion in human immunodeficiency virus type-l (HIV-l)-infected individuals progressing toward acquired immunodeficiency syndrome [AIDS). We have recently shown that CD95 (APO-I/Fas) expression is strongly increased in T cells of HIV-l-infected children. In this report we provide further evidence for a deregulated...

Managed care organizations (MCOs) may be incurring financial losses from persons with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) (PWHA). This study developed a statistical model to examine which specific comorbidities are important contributors to the variations in health care costs of PWHA. Individuals were classified into cost groups to simulate biased sel...